Skip to main content Skip to search Skip to main navigation

PIC/S: Guidance on Remote Assessments

PIC/S has published two guidance documents for inspectors: "Guidance on Remote Assessments" (PI 056-1) and "Aide Memoire on Remote Assessments" (PI 057-1). These documents will enter into force on 1 January 2025.

The PIC/S states that the remote assessment and hybrid inspection will have a place in an inspector‘s toolkit beyond the pandemic.

They soon will be available in our GMP knowledge portal, the GMP Compliance Adviser.

Guidance on remote assessments
The guidance distinguishes between fully interactive remote assessments, partially interactive remote assessments, desktop assessments, and hybrid inspections.
It covers the logistics and the technical requirements for remote inspections.

A feasibility check for a remote inspection using a risk assessment is mandatory. Factors to be considered include:

  • Previous inspection history
  • Activities carried out at site
  • Length of time since last on-site inspection
  • Information relating to the site from any regulatory authority / source
  • Changes since last inspection
  • Internet connectivity of site and of inspectors

Documentation requirements are also given. For example, the GMP certificate should clearly state whether the assessment/inspection was performed remotely, on-site or hybrid.

Aide Memoire on remote inspections
The Aide Memoire provides best practices and summaries for preparing and conducting remote assessments and post-inspection activities. It also provides prompts and questions to guide users through these processes.
Issues raised include, for example:

  • Pre-inspection teleconference with the site
  • Secure platform for sharing documents
  • Connectivity test
  • Need for an independent translator
  • Daily tentative schedule to ensure the availability of subject matter exterts (SMEs)
  • Site tours?
  • What type of document will be issued after the remote assessment

Source:

PIC/S: News

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ANVISA: Expands Recognition of Foreign GMP Authorities

ANVISA: Expands Recognition of Foreign GMP Authorities

Brazilian health authority ANVISA has updated the requirements for the recognition of Equivalent Foreign Regulatory Authorities (AREE) and the administrative procedures for Good Manufacturing Practice (GMP) certification (CBPF) through Normative Instruction IN 451/2026. The aim is to streamline and accelerate regulatory processes.
Read more
EDQM: Guidance on Reporting on Disappearances of Medicinal Products

EDQM: Guidance on Reporting on Disappearances of Medicinal Products

The EDQM has published guidance supporting the implementation of Recommendation CM/Rec(2024)3 on reporting medicinal products that disappear from the legal supply chain due to theft, loss or diversion. The initiative follows a European survey that identified shortcomings in reporting and co-ordination of such incidents.

Read more
Damage Control: Complaints and Recalls

Damage Control: Complaints and Recalls

Complaint handling and product recalls are important components of the Pharmaceutical Quality System (PQS). They serve to identify defective medicinal products and ensure that appropriate measures are taken to protect patient safety, as required by law and the competent supervisory authority.

Read more
What are the Phases of a Working Cycle During a Steam Sterilisation Process?

What are the Phases of a Working Cycle During a Steam Sterilisation Process?

Here's the answer:
Read more
EMA: 9 New Nitrosamines for Appendix 1

EMA: 9 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

The European Medicines Agency (EMA) published an update to its “Quality of Medicines: Questions and Answers – Part 2”. The revision concerns the section on “Reduced testing of incoming starting materials”.
Read more
Previous
Next